BidaskClub upgraded shares of Crispr Therapeutics (NASDAQ:CRSP) from a hold rating to a buy rating in a research note published on Thursday, January 4th.

A number of other equities analysts have also issued reports on CRSP. Cann reaffirmed a hold rating on shares of Crispr Therapeutics in a research report on Thursday, November 9th. Oppenheimer reiterated a hold rating on shares of Crispr Therapeutics in a research note on Thursday, December 21st. SunTrust Banks restated a hold rating and issued a $16.00 target price on shares of Crispr Therapeutics in a research note on Friday, November 10th. Barclays restated a buy rating and issued a $29.00 target price on shares of Crispr Therapeutics in a research note on Friday, September 8th. Finally, Piper Jaffray Companies initiated coverage on shares of Crispr Therapeutics in a research note on Friday, December 22nd. They issued an overweight rating on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Crispr Therapeutics presently has a consensus rating of Buy and a consensus target price of $22.81.

Crispr Therapeutics (NASDAQ CRSP) opened at $44.39 on Thursday. Crispr Therapeutics has a 52-week low of $11.63 and a 52-week high of $44.65. The firm has a market cap of $1,810.40, a P/E ratio of -33.63 and a beta of 4.64.

Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Wednesday, November 8th. The company reported ($0.62) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.02). Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The firm had revenue of $2.39 million during the quarter, compared to the consensus estimate of $3.61 million. During the same period in the prior year, the business earned ($2.77) EPS. The company’s revenue for the quarter was up 54.2% compared to the same quarter last year. equities analysts predict that Crispr Therapeutics will post -2.42 earnings per share for the current fiscal year.

In related news, insider Tyler Dylan-Hyde sold 66,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $28.03, for a total value of $1,849,980.00. Following the completion of the transaction, the insider now directly owns 25,204 shares in the company, valued at approximately $706,468.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Corp /De/ Celgene sold 1,112,446 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $18.98, for a total value of $21,114,225.08. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,234,504 shares of company stock valued at $44,388,553. 39.98% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in CRSP. Wells Fargo & Company MN boosted its position in Crispr Therapeutics by 459.7% during the 2nd quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock worth $128,000 after acquiring an additional 6,560 shares during the last quarter. Capital Investment Advisory Services LLC acquired a new position in Crispr Therapeutics during the 3rd quarter worth approximately $193,000. Ark Investment Management LLC acquired a new position in Crispr Therapeutics during the 2nd quarter worth approximately $206,000. Moloney Securities Asset Management LLC acquired a new position in Crispr Therapeutics during the 3rd quarter worth approximately $235,000. Finally, Creative Planning acquired a new position in Crispr Therapeutics during the 4th quarter worth approximately $243,000. 21.89% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Crispr Therapeutics (NASDAQ:CRSP) Lifted to “Buy” at BidaskClub” was originally published by Marea Informative and is the sole property of of Marea Informative. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.mareainformativa.com/2018/01/30/crispr-therapeutics-crsp-upgraded-at-bidaskclub-updated-updated-updated.html.

Crispr Therapeutics Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.